HK Stock Market Move | Heartcare-B (06609) surged more than 12%, expecting pre-tax profit to be around 80 million yuan in 2025, turning losses into profits year on year.

HEARTCARE-B(06609) surged over 12%, as of the time of writing, it increased by 11.54% to 56.55 Hong Kong dollars, with a turnover of 2.8647 million Hong Kong dollars. On the news front, XINWEI Medical announced that the group is expected to achieve revenue of approximately RMB 400 million to RMB 410 million for the year ending December 31, 2025, an increase of at least 43.9% year-on-year. The group's pre-tax profit is expected to be about RMB 80 million, turning losses into profits year-on-year. The revenue growth is mainly due to the launch of new products and technologies for ischemic stroke and the increase in market share of ischemic stroke products; the scale commercialization of intracranial stents and the increase in sales of other hemorrhagic stroke products; the continuous growth in sales of intervention pathway products; and the effective cost control measures implemented by the group to reduce expense ratios. In addition, XINWEI Medical also announced that the registration application for the self-expanding intracranial drug-eluting stent developed by the group has been accepted by the National Drug Administration. The self-expanding intracranial drug-eluting stent is used for the treatment of intracranial arterial atherosclerotic stenosis, providing support and opening of the narrow and obstructed lumens, and effectively preventing restenosis within the stent lumen. According to publicly available information, there are currently no similar products approved for sale globally, and the company's development progress for this type of product is at a leading level in the industry.